
Nkarta, Inc. – NASDAQ:NKTX
Nkarta stock price today
Nkarta stock price monthly change
Nkarta stock price quarterly change
Nkarta stock price yearly change
Nkarta key metrics
Market Cap | 162.66M |
Enterprise value | 228.56M |
P/E | -1.52 |
EV/Sales | N/A |
EV/EBITDA | -2.16 |
Price/Sales | N/A |
Price/Book | 0.49 |
PEG ratio | N/A |
EPS | -2.35 |
Revenue | N/A |
EBITDA | -124.75M |
Income | -116.20M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNkarta stock price history
Nkarta stock forecast
Nkarta financial statements
Jun 2023 | 0 | -33.28M | |
---|---|---|---|
Sep 2023 | 0 | -25.64M | |
Dec 2023 | 10.54M | -27.75M | -263.27% |
Mar 2024 | 0 | -29.51M |
Sep 2025 | 0 | -27.81M | |
---|---|---|---|
Oct 2025 | 0 | -27.19M | |
Dec 2025 | 0 | -34.34M | |
Dec 2025 | 0 | -27.36M |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 429038000 | 111.06M | 25.89% |
---|---|---|---|
Sep 2023 | 405864000 | 109.04M | 26.87% |
Dec 2023 | 378885000 | 105.6M | 27.87% |
Mar 2024 | 576936000 | 103.28M | 17.9% |
Jun 2023 | -21.77M | -3.17M | 395K |
---|---|---|---|
Sep 2023 | -20.27M | 29.42M | 0 |
Dec 2023 | -23.35M | 15.83M | 295K |
Mar 2024 | -28.50M | 21.48M | 226.26M |
Nkarta alternative data
Aug 2023 | 165 |
---|---|
Sep 2023 | 169 |
Oct 2023 | 169 |
Nov 2023 | 169 |
Dec 2023 | 167 |
Jan 2024 | 167 |
Feb 2024 | 167 |
Mar 2024 | 150 |
Apr 2024 | 150 |
May 2024 | 150 |
Jun 2024 | 150 |
Jul 2024 | 150 |
Nkarta other data
Period | Buy | Sel |
---|---|---|
Jun 2023 | 0 | 4030 |
Aug 2023 | 0 | 1331 |
Jan 2024 | 0 | 24875 |
Feb 2024 | 0 | 4143 |
Mar 2024 | 8000031 | 8367 |
Patent |
---|
Application Filling date: 7 Jan 2022 Issue date: 28 Jul 2022 |
Grant Filling date: 27 Mar 2018 Issue date: 21 Jun 2022 |
Grant Filling date: 4 Nov 2020 Issue date: 22 Feb 2022 |
Application METHODS FOR THE SIMULTANEOUS EXPANSION OF MULTIPLE IMMUNE CELL TYPES, RELATED COMPOSITIONS AND USES OF SAME IN CANCER IMMUNOTHERAPY Filling date: 22 Nov 2019 Issue date: 17 Feb 2022 |
Application Filling date: 10 Jun 2021 Issue date: 6 Jan 2022 |
Application Filling date: 11 Sep 2019 Issue date: 4 Nov 2021 |
Grant Filling date: 4 Nov 2020 Issue date: 26 Oct 2021 |
Grant Utility: Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy Filling date: 4 Nov 2020 Issue date: 12 Oct 2021 |
Application IMMUNE CELLS ENGINEERED TO EXPRESS CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY Filling date: 4 Nov 2020 Issue date: 11 Mar 2021 |
Application Filling date: 4 Nov 2020 Issue date: 11 Mar 2021 |
Nkarta: Finally An Attractive Valuation
Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
Nkarta: Possible Upside From H1 Update, If Positive
Fate Therapeutics: Getting There, But Perpetually
Nkarta: Going Down Despite Solid Data Due To Fate's Debacle
Nkarta: A Buy On Pullback With Valuation At Lows
Nkarta: Under The Radar Company With Brilliant Results
I-Mab Valuation Offers A Biotech Investment Opportunity
Nkarta: A Promising Natural Killer Cell Play
-
What's the price of Nkarta stock today?
One share of Nkarta stock can currently be purchased for approximately $2.34.
-
When is Nkarta's next earnings date?
Unfortunately, Nkarta's (NKTX) next earnings date is currently unknown.
-
Does Nkarta pay dividends?
No, Nkarta does not pay dividends.
-
How much money does Nkarta make?
Nkarta has a market capitalization of 162.66M.
-
What is Nkarta's stock symbol?
Nkarta, Inc. is traded on the NASDAQ under the ticker symbol "NKTX".
-
What is Nkarta's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Nkarta?
Shares of Nkarta can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Nkarta's key executives?
Nkarta's management team includes the following people:
- Mr. Paul J. Hastings Chief Executive Officer, Pres & Director(age: 65, pay: $820,100)
- Dr. Nadir Mahmood Ph.D. Chief Financial & Bus. Officer(age: 46, pay: $479,180)
- Dr. Alicia J. Hager Chief Legal Officer & Corporation Sec.(age: 55, pay: $420,630)
-
How many employees does Nkarta have?
As Jul 2024, Nkarta employs 150 workers.
-
When Nkarta went public?
Nkarta, Inc. is publicly traded company for more then 5 years since IPO on 10 Jul 2020.
-
What is Nkarta's official website?
The official website for Nkarta is nkartatx.com.
-
Where are Nkarta's headquarters?
Nkarta is headquartered at 6000 Shoreline Court, South San Francisco, CA.
-
How can i contact Nkarta?
Nkarta's mailing address is 6000 Shoreline Court, South San Francisco, CA and company can be reached via phone at +41 55824923.
Nkarta company profile:

Nkarta, Inc.
nkartatx.comNASDAQ
159
Biotechnology
Healthcare
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
South San Francisco, CA 94080
CIK: 0001787400
ISIN: US65487U1088
CUSIP: 65487U108